Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

SL-401 Mediates Potent Cytotoxicity Against CD123+ AML and MDS with Excess Blasts and Demonstrates Therapeutic Benefit in PDX Model

Rajeswaran Mani, DVM PhD, Swagata Goswami, MS, Bhavani Gopalakrishnan, Rahul Ramaswamy, Ronni Wasmuth, Minh Tran, Xiaokui Mo, PhD MAS, Amber Gordon, MLS, Donna Bucci, David Lucas, PhD, Christopher L. Brooks, PhD, Alison R. Walker, MD MPH, William Blum, MD, John C. Byrd, MD, Gerard Lozanski, MD, Sumithra Vasu, MBBS, Natarajan Muthusamy, DVM, PhD

Blood (2016) 128 (22): 580.

https://doi.org/10.1182/blood.V128.22.580.580

Published: 2016

Journal Articles

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy

Blood (2014) 123 (12): 1810–1817.

https://doi.org/10.1182/blood-2013-09-527853

Published: 2014

Includes: Supplemental data

Journal Articles

Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia

Blood (2012) 120 (23): 4621–4634.

https://doi.org/10.1182/blood-2012-05-429506

Published: 2012

Includes: Supplemental data

Journal Articles

Micro-RNA and Gene Expression In CLL: Network Analysis Elucidating the Complex Role of the NF-κB Signaling Pathway In Disease.

Erin K Hertlein, PhD, Lianbo Yu, Jianying Zhang, Amy J. Johnson, PhD, David Lucas, PhD, Guido Marcucci, MD, David Jarjoura, John C. Byrd, MD

Blood (2010) 116 (21): 3642.

https://doi.org/10.1182/blood.V116.21.3642.3642

Published: 2010

Journal Articles

Increased Incidence of Therapy Related Myeloid Neoplasia (t-MN) After Initial Therapy for CLL with Fludarabine-Cyclophosphamide (FC) Vs Fludarabine (F): Long-Term Follow-up of US Intergroup Study E2997

Blood (2010) 116 (21): 924.

https://doi.org/10.1182/blood.V116.21.924.924

Published: 2010

Journal Articles

Mcl-1 as a Possible Predictor of Progression-Free Survival in Previously Untreated Chronic Lymphocytic Leukemia Patients Treated with Pentostatin, Cyclophosphamide and Rituximab.

Farrukh Awan, MD, MS, Neil E. Kay, Melanie Davis, Wenting Wu, Nelson Leung, Diane F. Jelinek, Renee Tschumper, Charla Secreto, Thomas S. Lin, Michael R Grever, MD, Tait Shanafelt, MD, Clive S. Zent, Timothy G. Call, Nyla A. Heerema, PhD, Gerard Lozanski, John C. Byrd, MD, David Lucas, PhD

Blood (2008) 112 (11): 2105.

https://doi.org/10.1182/blood.V112.11.2105.2105

Published: 2008

Journal Articles

Protein Tyrosine Phosphatase Receptor Type O (PTPRO) Exhibits Tumor Suppressor Properties in K562 Cells by Dephosphorylating Bcr-Abl.

Sarmila Majumder, PhD, Tasneem Motiwala, Ph.D, Kalpana Ghoshal, Ph.D, Huban Kutay, Ph.D, Jharna Datta, Ph.D, David Lucas, Ph.D, John C. Byrd, M.D., Samson T. Jacob, Ph.D

Blood (2007) 110 (11): 2914.

https://doi.org/10.1182/blood.V110.11.2914.2914

Published: 2007

Journal Articles

Final Results of a Dose Escalation Study of Flavopiridol in Acute Leukemias Using a Novel Treatment Schedule.

William Blum, MD, Rebecca B. Klisovic, MD, Amy Johnson, PhD, Cheryl Kefauver, RN, Mitch Phelps, PhD, David Lucas, PhD, Lenguyen Huynh, Shujun Liu, PhD, James T. Dalton, PhD, Michael R. Grever, MD, Guido Marcucci, MD, John C. Byrd, MD

Blood (2007) 110 (11): 890.

https://doi.org/10.1182/blood.V110.11.890.890

Published: 2007

Journal Articles

OSU-HDAC42, a Novel Histone Deacetylase Inhibitor, Induces Apoptosis in a Caspase-Dependent Manner and Induces p 21WAF1/CIP1 and p16 Expression in Multiple Myeloma Cell Lines.

Valerie L. White, Shuhong Zhang, PhD, David Lucas, PhD, Ching-Shih Chen, PhD, Sherif S. Farag, MD, PhD

Blood (2006) 108 (11): 5078.

https://doi.org/10.1182/blood.V108.11.5078.5078

Published: 2006

Journal Articles

Updated Results of a Phase I Study of Flavopiridol in Acute Leukemias Using a Novel, Pharmacokinetically Derived Schedule: Clinical Activity Including Hyperacute Tumor Lysis Syndrome (TLS), Pharmacokinetics (PK), and Pharmacodynamics (PD).

William Blum, MD, Rebecca B. Klisovic, MD, Cheryl Kefauver, RN, Amy Johnson, PHD, Mitch Phelps, James T. Dalton, David Lucas, PHD, LeNguyen Huynh, Shujun Liu, Michael R. Grever, MD, A.D. Colevas, Guido Marcucci, MD, John C. Byrd, MD

Blood (2006) 108 (11): 4578.

https://doi.org/10.1182/blood.V108.11.4578.4578

Published: 2006

Journal Articles

Motexafin Gadolinium Induces Apoptosis in Lymphoid Cell Lines and Demonstrates Enhanced Biological Activity with Akt Kinase Inhibitors.

Louie Naumovski, MD-PhD, Jason Ramos, PhD, Jun Chen, PhD, Mint Sirisawad, BA, David Lucas, PhD, John C. Byrd, MD, Richard A. Miller, MD

Blood (2004) 104 (11): 3406.

https://doi.org/10.1182/blood.V104.11.3406.3406

Published: 2004

Journal Articles

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

Gerard Lozanski, Nyla A. Heerema, Ian W. Flinn, Lisa Smith, Jennifer Harbison, Jennifer Webb, Mollie Moran, Margaret Lucas, Thomas Lin, Marcy L. Hackbarth, John H. Proffitt, David Lucas, Michael R. Grever, John C. Byrd

Blood (2004) 103 (9): 3278–3281.

https://doi.org/10.1182/blood-2003-10-3729

Published: 2004

Journal Articles

Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia

Blood (2003) 101 (2): 425–432.

https://doi.org/10.1182/blood-2002-06-1899

Published: 2003

Journal Articles

The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction

John C. Byrd, Shinichi Kitada, Ian W. Flinn, Jennifer L. Aron, Michael Pearson, David Lucas, John C. Reed

Blood (2002) 99 (3): 1038–1043.

https://doi.org/10.1182/blood.V99.3.1038

Published: 2002

NARROW

SL-401 Mediates Potent Cytotoxicity Against CD123+ AML and MDS with Excess Blasts and Demonstrates Therapeutic Benefit in PDX Model

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy

Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia

Micro-RNA and Gene Expression In CLL: Network Analysis Elucidating the Complex Role of the NF-κB Signaling Pathway In Disease.

Increased Incidence of Therapy Related Myeloid Neoplasia (t-MN) After Initial Therapy for CLL with Fludarabine-Cyclophosphamide (FC) Vs Fludarabine (F): Long-Term Follow-up of US Intergroup Study E2997

Mcl-1 as a Possible Predictor of Progression-Free Survival in Previously Untreated Chronic Lymphocytic Leukemia Patients Treated with Pentostatin, Cyclophosphamide and Rituximab.

Protein Tyrosine Phosphatase Receptor Type O (PTPRO) Exhibits Tumor Suppressor Properties in K562 Cells by Dephosphorylating Bcr-Abl.

Final Results of a Dose Escalation Study of Flavopiridol in Acute Leukemias Using a Novel Treatment Schedule.

OSU-HDAC42, a Novel Histone Deacetylase Inhibitor, Induces Apoptosis in a Caspase-Dependent Manner and Induces p 21WAF1/CIP1 and p16 Expression in Multiple Myeloma Cell Lines.

Updated Results of a Phase I Study of Flavopiridol in Acute Leukemias Using a Novel, Pharmacokinetically Derived Schedule: Clinical Activity Including Hyperacute Tumor Lysis Syndrome (TLS), Pharmacokinetics (PK), and Pharmacodynamics (PD).

Motexafin Gadolinium Induces Apoptosis in Lymphoid Cell Lines and Demonstrates Enhanced Biological Activity with Akt Kinase Inhibitors.

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia

The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only